News
Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback